Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

RemeGen Says ADC Successfully Targets Mesothelin in Solid Tumors

publication date: Jun 4, 2024

Yantai RemeGen reported positive data from a first-in-human China Phase I/II trial of RC88, an ADC that targets mesothelin (MSLN) and delivers a monomethyl auristatin E (MMAE) payload. MSLN, a glycosylphosphatidylinositol-anchored protein, is overexpressed in several solid tumors with limited expression in normal tissues. The trial enrolled 170 patients with ovarian, non-small cell lung and cervical cancers who had previously failed other therapies. Currently, chemotherapy is the standard of care for ovarian cancer with an overall response rate of 12%, while RC88 recorded a 42% ORR in the trial. More details....

Stock Symbols: (HK: 9995; SHA: 688331)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital